✨ Free AI Report
Aptevo Therapeutics Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Aptevo Therapeutics Inc.
Research Preview

Aptevo Therapeutics Inc.: Business Overview, Financials & Competitive Analysis

Aptevo Therapeutics is a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary ADAPTIR platform technologies. The company's lead clinical candidate, mipletamig, is...

Analyst-debate audio for Aptevo Therapeutics Inc.

AskCyborg analysts argue the bull and bear cases for Aptevo Therapeutics Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Aptevo Therapeutics Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
3/ 10Challenged

Cyborg Score thesis

Early-stage immuno-oncology player with differentiated multispecific platform and encouraging AML data, but severe cash burn and...

Read the full analyst-debate transcript →
Industry Oncology Drugs
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Aptevo Therapeutics Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Aptevo Therapeutics Inc. Overview

Pro stress-test →

Aptevo Therapeutics is a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary ADAPTIR platform technologies. The company's lead clinical candidate, mipletamig, is currently being evaluated in frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine.

Strategic Profile

Pro stress-test →

Aptevo's pipeline is generated from its proprietary ADAPTIR and ADAPTIR-FLEX platforms and includes bispecific and trispecific candidates designed to create multiple oncology value drivers across hematologic malignancies and solid tumors. The company expanded its development strategy through a 50/50 collaboration with Niowave to develop up to three radiopharmaceutical oncology programs, giving Aptevo a capital-efficient way to enter radiopharmaceutical therapeutics.

Competitive Landscape

Pro stress-test →

Aptevo competes in the clinical-stage immuno-oncology space against companies developing multispecific antibodies and cellular immunotherapies for cancer. Key competitors include Zymeworks, CytomX Therapeutics, and Allogene Therapeutics, which pursue overlapping cell-engager and bispecific antibody approaches. Aptevo's differentiation lies in its proprietary ADAPTIR platform enabling rapid generation of multispecific candidates and its emerging radiopharmaceutical strategy through the Niowave partnership.

Industry Context

Aptevo Therapeutics Inc. operates in Oncology Drugs.

Key facts

Headquarters: Seattle, WA · Revenue: No revenue (pre-commercial clinical-stage company) · Market cap: $5.55M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Aptevo Therapeutics Inc..

+1 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Aptevo Therapeutics Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

ZymeworksBispecific and multispecific therapeutic platform for cancer→CytomX TherapeuticsProbody-masked T-cell engager platform for solid tumors→Allogene TherapeuticsAllogeneic CAR-T cell therapies for hematologic malignancies→

Compare Aptevo Therapeutics Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Aptevo Therapeutics Inc. operates in Oncology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Oncology Drugs research →
NEW · MCP server

Ask your AI assistant about Aptevo Therapeutics Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Aptevo Therapeutics Inc. and its top competitor on Cyborg Score”
“What did Aptevo Therapeutics Inc. do this quarter?”
“Is Aptevo Therapeutics Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Aptevo Therapeutics Inc. do?+
Aptevo Therapeutics is a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary ADAPTIR platform technologies. The company's lead clinical candidate, mipletamig, is...
What is Aptevo Therapeutics Inc.'s Cyborg Score?+
Aptevo Therapeutics Inc. has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Aptevo Therapeutics Inc.'s main competitors?+
Named competitors include Zymeworks, CytomX Therapeutics, Allogene Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full Aptevo Therapeutics Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Aptevo Therapeutics Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Aptevo Therapeutics Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Oncology Drugs research

Companies in the same sector and named competitors, ranked by Cyborg Score.

5Zymeworks Inc.